Cingulate Inc. (CING) is a clinical-stage biopharmaceutical company based in Kansas City, Kansas, developing treatments for ADHD and anxiety using its Precision Timed Release drug-delivery platform. It is covered by a small group of analysts whose views are exceptionally wide-ranging.
Across five analyst targets, the calculated mean is roughly $21.20, which rounds to a $21 central target. The approximate range runs from $8 to $44, underscoring how divergent the estimates are. Verified individual targets include Roth MKM's $9 (August 2026), Maxim Group's $8 (August 2026), H.C. Wainwright's $20 (May 2026), and Ascendiant Capital, which cut its target from $58 to $55 in April 2026. Aggregators such as S&P Global data through Investing.com and StockAnalysis report a consensus "Strong Buy" rating with a mean near $21.
The gap between the lowest and highest targets reflects different assumptions about the probability that CTx-1301 (dexmethylphenidate) clears Phase 3 trials, wins regulatory approval, and captures market share in a competitive ADHD category. Lower targets discount the stock for clinical and financing risk, while higher targets model commercial success for multiple pipeline candidates.
The stock closed near $5.53 in late October 2026, with a market capitalization around $80 million and about 14.5 million shares outstanding. Its 52-week range is $3.16 to $11.89. From a price near $5.53, the $21 target implies roughly 280% upside, which is a very large move requiring a step-change in the company's fundamental value rather than a modest re-rating.
The path toward such a level would depend on clinical catalysts. Cingulate generates no product revenue and reported a net loss of roughly $28.8 million over the trailing twelve months. A move toward the target would most plausibly be driven by positive Phase 3 data for CTx-1301, followed by a regulatory filing and, ultimately, commercialization. Valuation would shift from a pre-revenue, clinical-stage framework to one based on projected sales and peak-market opportunity.
The stock trades well below its 52-week high of $11.89 and above its 52-week low of $3.16. The 200-day moving average sits near $5.43, meaning the stock is only modestly above its longer-term trend level. A psychological and technical resistance zone exists near the prior high around $11.89; a durable break above that would be needed before the stock could begin trading toward levels implied by higher analyst targets. On the downside, the $3.16 low and the sub-$4 zone represent key support areas.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual analysts may model different time frames and probability-weighted scenarios. Investors should monitor Phase 3 trial results and any interim readouts for CTx-1301, updates on CTx-2103 (buspirone) for anxiety, quarterly cash balances and financing activity, and any analyst target revisions. Regulatory milestones and competitive developments in the ADHD market are also important. No timing should be assumed for reaching the target.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive name like Cingulate, such tools can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Traders seeking a systematic view of daily signals can explore these AI-generated insights to complement their own research.
The $21 target represents the rounded average of the analyst price targets reviewed, but the range of roughly $8 to $44 shows that analysts are far from aligned on CING's future. Reaching $21 would require a very large move of about 280% from the recent price near $5.53, hinging overwhelmingly on successful Phase 3 data for CTx-1301 and a path to commercialization. Positive clinical results and a large ADHD market support the bullish case, while cash burn, financing risk, competition, and binary clinical outcomes are the principal obstacles. Investors should watch trial readouts, financing activity, and analyst revisions before drawing conclusions, as the outcome remains uncertain and no target is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that CING and CTMX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CING and CTMX's prices will move in lockstep.
| Ticker / NAME | Correlation To CING | 1D Price Change % | ||
|---|---|---|---|---|
| CING | 100% | +2.47% | ||
| CTMX - CING | 32% Poorly correlated | N/A | ||
| ELVN - CING | 29% Poorly correlated | -0.68% | ||
| PLX - CING | 28% Poorly correlated | +11.28% | ||
| SABS - CING | 27% Poorly correlated | -0.97% | ||
| TGTX - CING | 27% Poorly correlated | +1.39% | ||
More | ||||